재발한 위장관 간질성 종양(GISTs) 환자들의 임상양상 분석

다국어 초록 (Multilingual Abstract)

Purpose: Gastrointestinal stromal tumors (GISTs) are of a mesenchymal origin, and they arise predominantly from the gastrointestinal tract. This study aims to aid the post operative management of GIST patients by analyzing the clinical and immunopathological features of recurrent GISTs.
Methods: We enrolled 98 GIST patients who had been operated on for their primary tumor from 1987 to 2001 at the Catholic Medical Center. Among them, 28 patients had clinical and radiological features that were proved to be recurrence, and the patients’ survival rates were compared according to the treatment modalities.
Results: When the maximum length of tumor was shorter and the mitotic index lower, then these patients had higher disease free survival rates and lower recurrence rates. The Ki-67 negative group had lower recurrence rates than their Ki-67 positive counterparts. Recurrence was mostly observed as liver metastasis. The mean length of time to recur was 22.96 months. Fifteen patients received additional treatments such as surgery, chemotherapy and radiation therapy, but there was no significant difference in survival rates when they were compared to the 13 patients who did not receive further treatments.
Conclusion: Of the patients diagnosed with GIST after surgery, those with worse prognostic factors, i.e. a bigger tumor size and higher mitotic index, require more meticulous surveillance for tumor recurrence, and especially for liver recurrence, which was the most common recurrence site, during the follow up exams. In addition, although there have not been any remarkably effective treatments for the recurrent GIST patients, further researches for new therapy such as STI-571 is mandated.

목차 (Table of Contents)

• 서론
• 방법
• 결과
• 고찰
• 결론
• REFERENCES

참고문헌 (Reference)

1 DeMatteo RP, "Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival" 231 : 51-58, 2000

2 Mochizuki Y, "Treatment and risk factors for recurrence after curative resection of gastrointestinal stromal tumors of the stomach" 28 : 870-875, 2004

3 Pierie JP, "The effect of surgery and grade on outcome of gastrointestinal stromal tumors" 136 : 383-389, 2001

4 Eilber FC, "Surgical resection and intraperitoneal chemotherapy for recurrent abdominal sarcomas" 6 : 645-650, 1999

5 Rajan DK, "Sarcomas metastatic to the liver: response and survival after cisplatin, doxorubicin, mitomycin-C, ethiodol, and polyvinyl alcohol chemoembolization" 12 : 187-193, 2001

6 Mudan SS, "Salvage surgery for patients with recurrent gastrointestinal sarcoma: prognostic factors to guide patient selection" 88 : 66-74, 2000

7 Eilber FC, "Recurrent gastrointestinal stromal sarcomas" 9 : 71-95, 2000

8 Verweij J, "Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial" 364 : 1127-1134, 2004

9 Ng EH, "Prognostic implications of patterns of failure for gastrointestinal leiomyosarcomas" 69 : 1334-1341, 1992

10 Ng EH, "Prognostic factors influencing survival in gastrointestinal leiomyosarcomas. Implications for surgical management and staging" 215 : 68-77, 1992

11 Langer C, "Prognostic factors influencing surgical management and outcome of gastrointestinal stromal tumors" 90 : 332-339, 2003

12 Emory TS, "Prognosis of gastrointestinal smooth-muscle(stromal) tumors: dependence on anatomic site" 23 : 82-87, 1999

13 Panizo-Santos A, "Predicting metastatic risk of gastrointestinal stromal tumors: Role of cell proliferation and cell cycle regulatory proteins" 8 : 133-144, 2000

14 Scaife CL, "Is there a role for surgery in patients with “unresectable” cKIT+ gastrointestinal stromal tumors treated with imatinib mesylate?" 186 : 665-669, 2003

15 Rudolph P, "Immunophenotype, proliferation, DNA-ploidy, and biological behavior of gastrointestinal stromal tumors: a multivariate clinicopathologic study" 29 : 791-800, 1998

16 Rudolph P, "Immunophenotype, proliferation, DNA-ploidy, and biological behavior of gastrointestinal stromal tumors: a multivariate clinicopathologic study" 29 : 791-800, 1998

17 Suster S, "Gastrointestinal stromal tumors" 13 : 297-313, 1996

18 van der Zwan SM, "Gastrointestinal stromal tumor: 5 years later" 104 (104): 1781-1788, 2005

19 Thomas RM, "Gastrointestinal cancer; incidence and prognosis by histologic type, SEER population-based data 1973-1987" 75 : 154-170, 1987

20 Blay JY, "GIST consensus meeting panelists. Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Consensus Conference of 20-21 March 2004, under the auspices of ESMO" 16 : 566-578, 2005

21 Miettinen M, "Evaluation of malignancy and prognosis of gastrointestinal stromal tumor: a review" 33 : 478-483, 2002

22 Samiian L, "Evaluation of gastrointestinal stromal tumors for recurrence rates and patterns of long-term follow-up" 70 : 187-191, 2004

23 Demetri GD, "Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors" 347 : 472-480, 2002

24 Joenssu H, "Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor" 344 : 1052-1056, 2001

25 Fletcher CD, "Diagnosis of gastrointestinal stromal tumors: A consensus approach" 33 : 459-465, 2002

26 Dematteo RP, "Clinical management of gastrointestinal stromal tumors: Before and after STI-571" 33 : 466-477, 2002